ReviewEndocrine, metabolic & immune disorders drug targets2026
Core Needle Biopsy (CNB) and Immunohistochemical Markers in Indeterminate Thyroid Nodules: Evidence and Perspectives.
Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid nodules are a prevalent endocrine condition that requires accurate diagnostic tools to guide appropriate clinical management. Despite advances in imaging and cytology, evaluating thyroid nodules remains challenging, particularly in cases with indeterminate cytology. This narrative review examines the effectiveness of core needle biopsy (CNB) as a diagnostic approach, with a specific focus on its integration with immunohistochemical markers. CNB offers high diagnostic accuracy that improves with operator experience. The inclusion of immunohistochemical markers (CK19, CD56, Galectin-3, and HBME1) further enhances diagnostic precision, particularly in stratifying indeterminate nodules. However, CNB cannot reliably distinguish follicular adenoma from follicular carcinoma preoperatively because diagnosis requires evaluation of complete capsular and/or vascular invasion on the surgical specimen, which remains a fundamental limitation for follicular-patterned nodules. Despite its accuracy, broader adoption remains limited by non-standardized CNB protocols, inter-observer variability for IHC interpretation, and heterogeneous reimbursement policies across health systems, especially outside Western contexts. Comparative data on patient-reported outcomes and local cost-effectiveness in Asian and Indian settings are still variable and require multicenter validation before routine implementation can be generalized. The findings of this review reinforce the growing evidence that supports CNB as an effective diagnostic tool for thyroid nodules, especially when combined with immunohistochemical markers. This approach has the potential to improve diagnostic accuracy, reduce unnecessary surgical interventions, and enhance patient outcomes. Future research should focus on standardizing procedures and conducting large-scale validation studies.
Indexed as
Identifiers
42003660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.